<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11242">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590044</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00005062a</org_study_id>
    <nct_id>NCT00590044</nct_id>
  </id_info>
  <brief_title>Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)</brief_title>
  <official_title>Basal Insulin in the Management of Patients With Diabetic Ketoacidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic ketoacidosis (DKA) is the most serious emergency in patients with diabetes. With an
      estimated 100,000 admissions per year in the United States, DKA is also the leading cause of
      death in children with type 1 diabetes, and accounts for a significant proportion of
      admissions in adult patients with type 1 and type 2 diabetes. The mainstay in the treatment
      of DKA involves the continuous intravenous (IV) infusion of regular insulin or the frequent
      subcutaneous (SC) injections of regular or rapid-acting insulin analogs. Multiple studies
      have reported successful protocols for insulin administration during the acute management of
      DKA, but they have failed to address the transition phase from IV to SC maintenance insulin
      regimen. The American Diabetes Association (ADA) position statement recommends the use of
      split-mixed insulin combination of regular and intermediate-acting insulin (NPH). This
      regimen, however, are associated with a high rate of hyperglycemia shortly after
      discontinuation of IV insulin and a risk of hypoglycemia during the hospital stay. Recently,
      the long-acting &quot;basal&quot; insulin glargine (Lantus®, Sanofi Aventis Pharmaceuticals) has been
      shown to facilitate glycemic control with lower rate of hypoglycemic events than
      intermediate-acting insulin in subjects with type 1 and type 2 diabetes. This study aims i)
      to determine the effects of giving a dose of glargine insulin shortly after starting an
      intravenous insulin infusion on glycemic control, time to resolve DKA, and rate of
      hypoglycemia in patients with DKA, and ii) to compare the safety and efficacy of basal/bolus
      (glargine/glulisine) insulin versus the standard split-mixed insulin regimen of NPH and
      regular insulin after the resolution of DKA. The hypothesis is that basal (lantus®) insulin
      as compared to NPH insulin shortly after the start of insulin infusion will improve
      inpatient glycemic control in patients with DKA.

      This investigator initiated research will be conducted at Grady Memorial Hospital, Atlanta
      and at University of Minnesota, MN. Dr Umpierrez designed the study and will serve as
      principal investigator. A total of 40 patients will be recruited at each site.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Daily Blood Glucose Concentration After the Resolution of DKA</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome during the subcutaneous (SC) period (the primary outcome measurement) was to determine differences in glycemic control as measured by mean daily blood glucose(BG) concentration between treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Blood Glucose Concentration While on the Insulin Drip</measure>
    <time_frame>blood glucose (BG) before meals and at bedtime</time_frame>
    <safety_issue>No</safety_issue>
    <description>determine differences in glycemic control as measured by differences in the mean daily blood glucose levels between treatment groups (insulin drip with regular insulin vs glulisine insulin) during the acute phase of diabetic ketoacidosis(DKA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Hypoglycemia</measure>
    <time_frame>blood glucose (BG) before meals, at bedtime and as needed</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>differences between treatment groups in the number of hypoglycemic events (blood glucose &lt; 60 mg/dl) between hours 12 to 36 (second day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Hyperglycemia</measure>
    <time_frame>blood glucose (BG) before meals, at bedtime and as needed</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>differences between treatment groups in the number of hyperglycemic episodes (blood glucose &gt; 200 mg/dl).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Diabetic Ketoacidosis</condition>
  <arm_group>
    <arm_group_label>glargine (Lantus) + glulisine (Apidra)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily insulin glargine (Lantus) + glulisine (Apidra) before meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Split-mixed NPH + Regular insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Split-mixed NPH + Regular insulin twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine+ glulisine</intervention_name>
    <description>Daily insulin glargine + glulisine before meals</description>
    <arm_group_label>glargine (Lantus) + glulisine (Apidra)</arm_group_label>
    <other_name>glargine (Lantus) + glulisine (Apidra)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH + Regular insulin</intervention_name>
    <description>Split-mixed NPH + Regular insulin twice daily</description>
    <arm_group_label>Split-mixed NPH + Regular insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients admitted to Grady Memorial Hospital who meet diagnosis criteria of DKA
             and who are willing to participate in the study protocol will be considered
             candidates for inclusion into the study.

          -  Diagnostic Criteria for DKA: Blood glucose &gt; 250 mg/dL, arterial or venous pH &lt; 7.3,
             serum bicarbonate &lt; 18 mEq/L, and moderate to severe ketonemia (acetoacetate ≥ 1:4 or
             β-hydroxybutyrate &gt; 3 mmol).

        Exclusion Criteria:

          -  Hemodynamic instability (MAP &lt; 50 or patients requiring pressor)

          -  Significant identifiable medical or surgical illness, including but not limited to:
             acute myocardial infarction, congestive heart failure; respiratory failure requiring
             mechanical ventilation; acute or chronic renal insufficiency (serum creatinine &gt; 3.0
             mg/dl); end stage liver failure, and cirrhosis.

          -  Patients with dementia or persistent altered mental status that would prevent
             collection of consent form and reliable information.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University SOM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sidney Jones, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota School of Medicine</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>December 28, 2007</firstreceived_date>
  <firstreceived_results_date>January 30, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetic ketoacidosis</keyword>
  <keyword>insulin therapy</keyword>
  <keyword>DKA</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Ketoacidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glargine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glargine (Lantus) + Glulisine</title>
          <description>Daily insulin glargine (Lantus) + glulisine (Apidra) before meals</description>
        </group>
        <group group_id="P2">
          <title>NPH + Regular</title>
          <description>Split-mixed NPH + Regular insulin twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>wrong insulin arm assigned</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glargine (Lantus) + Glulisine</title>
          <description>Daily insulin glargine (Lantus) + glulisine (Apidra) before meals</description>
        </group>
        <group group_id="B2">
          <title>NPH + Regular</title>
          <description>Split-mixed NPH + Regular insulin twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="74"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="74"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39" spread="12"/>
                <measurement group_id="B2" value="38" spread="12"/>
                <measurement group_id="B3" value="38.5" spread="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="74"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Blood Glucose Concentration While on the Insulin Drip</title>
        <description>determine differences in glycemic control as measured by differences in the mean daily blood glucose levels between treatment groups (insulin drip with regular insulin vs glulisine insulin) during the acute phase of diabetic ketoacidosis(DKA)</description>
        <time_frame>blood glucose (BG) before meals and at bedtime</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Hypoglycemia</title>
        <description>differences between treatment groups in the number of hypoglycemic events (blood glucose &lt; 60 mg/dl) between hours 12 to 36 (second day)</description>
        <time_frame>blood glucose (BG) before meals, at bedtime and as needed</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Daily Blood Glucose Concentration After the Resolution of DKA</title>
        <description>The primary outcome during the subcutaneous (SC) period (the primary outcome measurement) was to determine differences in glycemic control as measured by mean daily blood glucose(BG) concentration between treatment groups.</description>
        <time_frame>1 year</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Glargine (Lantus) + Glulisine</title>
            <description>Daily insulin glargine (Lantus) + glulisine (Apidra) before meals</description>
          </group>
          <group group_id="O2">
            <title>NPH + Regular</title>
            <description>Split-mixed NPH + Regular insulin twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Daily Blood Glucose Concentration After the Resolution of DKA</title>
            <description>The primary outcome during the subcutaneous (SC) period (the primary outcome measurement) was to determine differences in glycemic control as measured by mean daily blood glucose(BG) concentration between treatment groups.</description>
            <units>mg/dl</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="124" spread="41"/>
                  <measurement group_id="O2" value="190" spread="45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Hyperglycemia</title>
        <description>differences between treatment groups in the number of hyperglycemic episodes (blood glucose &gt; 200 mg/dl).</description>
        <time_frame>blood glucose (BG) before meals, at bedtime and as needed</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Glargine (Lantus) + Glulisine</title>
          <description>Daily insulin glargine (Lantus) + glulisine (Apidra) before meals</description>
        </group>
        <group group_id="E2">
          <title>NPH + Regular</title>
          <description>Split-mixed NPH + Regular insulin twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Umpierrez</name_or_title>
      <organization>Emory University SOM</organization>
      <phone>4047781663</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
